Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. The company has completed Phase III clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis. Zerenex is also in Phase II development for the management of phosphorus and iron deficiency in anemic patients with stages three to five non-dialysis dependent chronic kidney diseases. The company has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. It also has strategic alliances with Panion & BF Biotech, Inc.; Japan Tobacco Inc.; and Torii Pharmaceutical Co., Ltd. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.

Key Statistics